+91-8668442535

Diabetes Drugs Market By Type Of Therapy (Insulin, Oral Hypoglycemic Drugs (Anti-Diabetes Drugs), Non-Insulin Injectable Anti-Diabetes Drugs, Others) - Growth, Future Prospects, And Competitive Analysis, 2017 - 2025

Diabetes is a prolonged, enduring disease characterized by high blood glucose levels arising when the pancreas is no longer capable of secreting insulin, a key hormone that processes glucose to produce energy. The inability to produce or use insulin effectively results in a high blood glucose level (hyperglycemia). Over the long term, high blood glucose levels can damage the blood vessels in the heart, kidneys, eyes, or nervous system. The global diabetes drugs market is emerging at an impressive pace because of an intensifying diabetes population, leading to increased demand for diabetic care. Apart from the availability of an array of existing drugs, widespread R&D projects for new diabetes investigative methods have given the industry a boost.

This research study titled "Diabetes Drugs Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025" states the detailed analysis that helps investors, developers, company executives, and industry participants in making decisions related to the prospects in the global diabetes drugs market and to take strategic initiatives. This report examines and offers the foremost trends prevalent in the global diabetes drugs market, as well as the market's size and forecast.

The scope of the report comprises types of therapy and geographical distribution. The types of therapy segments are further categorized into insulin, oral hypoglycemic drugs (anti-diabetic drugs), non-insulin injectable anti-diabetes drugs, and others. An in-depth analysis in terms of market size and forecast is done for each segment for the duration of 2015–2025, and particular CAGRs for the duration of 2017–2025 are also presented in the report.

The scope of this report also covers geographical segments along with major countries, which are alluded to as follows:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • U.K.
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • India
    • China
    • Japan
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

A description of the market estimation of the above-mentioned segment for the duration of 2015–2025 is covered in the scope of the report, along with the individual market estimations for the respective countries in the regional segments.

The report also includes a detailed description of market dynamics to help readers understand and anticipate market trends. Tools for conducting a portfolio analysis by the key player are also demonstrated in the reports. This report also includes company profiles of the major market players who hold prominent positions in the global diabetes drugs market. The major players in the global diabetes drugs market are AstraZeneca plc, Biocon Limited, Boston Therapeutics, Inc., Cadila Healthcare, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Lupin Limited, Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Ranbaxy Laboratories Limited, Sanofi S.A., and Takeda Pharmaceutical Company Ltd., among others.

Based on the type of therapy, the global diabetes drugs market is segmented as follows:

  • Insulin
  • Oral hypoglycemic drugs (anti-diabetes drugs)
  • Non-insulin injectable anti-diabetes drugs
  • Others

In 2016, insulin dominated the market due to the continuous market entry of novel drug therapies, the most convenient mode of treatment, and rising demand for targeted therapy and biological drugs. The growth of the diabetes drug market has been strongly supported by novel drug therapies like anti-diabetes drugs and more. One major factor that contributes to the growth of diabetes drugs is increased life expectancy. Because populations are rapidly aging, the incidence and prevalence of many chronic diseases are bound to rise, driving up demand for diabetes drugs. Additionally, it is not just the geriatric population that is making a choice for diabetes drugs; an increasing incidence is also being noticed in adolescents, which is also supporting the growth of the market.

Diabetes medicine is a general treatment for people who are suffering from diabetes. Various types of diabetes or anti-diabetes drugs are available, each with its own mechanism of action that helps the patient keep the condition under control. The method of administration may vary, with some drugs being injected directly into the bloodstream and others being taken orally. The global diabetes drugs market is emerging at an impressive pace because of intensifying diabetic population growth, aging, unhealthy diets, obesity, and a sedentary lifestyle, which result in increasing demand for diabetic drugs and a larger market.

Geographically, the global diabetes drugs market is cumulative for Europe, North America, Asia Pacific, the Middle East, Africa, and Latin America.

In 2016, North America and Europe accounted for the major share of the global diabetes drugs market, followed by Asia Pacific due to key driving factors such as the rising prevalence of diabetes, high awareness associated with early diabetes diagnosis and treatment, and supportive reimbursement policies. The International Diabetes Federation estimates that in 2017, about 82 million people were diagnosed in Asia and the Pacific, and about 1.1 million deaths occurred. Due to the perpetual growth in the incidence of diabetes, the demand for novel drug therapies is expected to increase in the near future. During the forecast period of 2017–2025, Asia Pacific was observed as the fastest-growing region due to key driving factors such as the rising prevalence of diabetes in developing countries, increasing awareness associated with an early diabetes diagnosis, developing healthcare infrastructure, and mounting demand for novel drug therapies.

The detailed geographical classification of the global diabetes drugs market is as follows:

  • North America (U.S. and Canada)
  • Asia Pacific (Japan, India, China, and the Rest of Asia Pacific)
  • Europe (France, Germany, the U.K., Spain, Italy, and the Rest of Europe)
  • Latin America (Mexico, Brazil, and the Rest of Latin America)
  • Middle East and Africa (GCC plus the rest of the Middle East and Africa) 

Frequently Asked Questions:

The market for Diabetes Drugs Market is expected to reach US$ 49.26 Bn By 2025.

The Diabetes Drugs Market is expected to see significant CAGR growth over the coming years, at XX%.

The report is forecasted from 2017-2025.

The base year of this report is 2016.

Boston Therapeutics, Inc., Cadila Healthcare, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Lupin Limited, Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Ranbaxy Laboratories Limited, Sanofi S.A., are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Nov 2017
Category:  Pharmaceuticals
Report ID:   58812
Report Format:   PDF
Pages:   120
Rating:    4.8 (80)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support